Noxopharm Annual Report 2022

Annual Report 2022 25 Consolidated Note 2022 $ 2021 $ Assets Current assets Cash and cash equivalents 7 14,010,668 26,795,785 Trade and other receivables 8 5,213,381 5,799,224 Other assets 9 1,609,279 379,027 Total current assets 20,833,328 32,974,036 Non-current assets Financial assets at fair value through profit and loss 10 5,415,033 14,272,419 Plant and equipment 84,782 135,111 Right-of-use assets 137,102 349,308 Term deposit pledged for bank guarantee 123,512 122,837 Total non-current assets 5,760,429 14,879,675 Total assets 26,593,757 47,853,711 Liabilities Current liabilities Trade and other payables 11 1,795,721 6,130,170 Lease liability building 160,624 231,666 Employee entitlements 324,502 445,359 Total current liabilities 2,280,847 6,807,195 Non-current liabilities Lease liability building - 117,642 Employee entitlements 194,966 152,499 Total non-current liabilities 194,966 270,141 Total liabilities 2,475,813 7,077,336 Net assets 24,117,944 40,776,375 Equity Issued capital 12 74,635,721 72,622,560 Reserves 13 8,285,254 8,487,119 Accumulated losses (58,803,031) (40,333,304) Total equity 24,117,944 40,776,375 Statement of Financial Position

RkJQdWJsaXNoZXIy MjE2NDg3